Repligen Co. (NASDAQ:RGEN) Stock Holdings Lowered by Baird Financial Group Inc.

Baird Financial Group Inc. cut its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 7.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 354,237 shares of the biotechnology company's stock after selling 28,373 shares during the period. Baird Financial Group Inc. owned approximately 0.63% of Repligen worth $50,989,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after acquiring an additional 743,815 shares during the last quarter. Vanguard Group Inc. increased its position in Repligen by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock worth $734,251,000 after purchasing an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC raised its holdings in Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after buying an additional 122,595 shares during the period. Alliancebernstein L.P. lifted its position in Repligen by 23.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock valued at $145,508,000 after buying an additional 191,439 shares in the last quarter. Finally, Conestoga Capital Advisors LLC grew its stake in Repligen by 0.7% during the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock worth $136,395,000 after buying an additional 6,872 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Down 3.6 %

NASDAQ:RGEN traded down $4.61 during mid-day trading on Friday, reaching $123.24. The stock had a trading volume of 580,989 shares, compared to its average volume of 727,651. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $6.92 billion, a price-to-earnings ratio of -241.65, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The stock's 50 day simple moving average is $135.03 and its two-hundred day simple moving average is $145.37.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business's revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 EPS. Equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on RGEN shares. JPMorgan Chase & Co. cut their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Canaccord Genuity Group decreased their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Royal Bank of Canada dropped their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Finally, Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research note on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $173.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.